Casgevy gains UK label expansion for younger patient population
Patients with β-thalassemia and sickle cell disease aged five and up can now receive Vertex Pharmaceuticals and CRISPR Therapeutics gene therapy.
Cytiva Navigating cell therapy WP 4
Estuary secures $103m to advance kidney disease gene therapies
CAR-T specialist Caribou culls pipeline and seeks exit deal
FDA approves first gene therapy for Sanfilippo syndrome type A
Cellares and GenomeFrontier to assess automated GF-CART01 production
Encoded secures $275m for Dravet syndrome gene therapy
Typewriter raises $56m Series A to progress non-viral gene therapy platform
FDA places clinical hold on Regenxbio’s RGX-121 in MPS II trial
